The Goldman Sachs Group Has Lowered Expectations for Vaxcyte (NASDAQ:PCVX) Stock Price

Vaxcyte (NASDAQ:PCVX - Get Free Report) had its target price lowered by equities researchers at The Goldman Sachs Group from $138.00 to $100.00 in a research report issued on Tuesday,Benzinga reports. The firm currently has a "buy" rating on the stock. The Goldman Sachs Group's price target points to a potential upside of 216.46% from the company's current price.

PCVX has been the topic of a number of other research reports. Guggenheim restated a "buy" rating and issued a $160.00 target price on shares of Vaxcyte in a research note on Wednesday, March 12th. Bank of America cut their price objective on Vaxcyte from $157.00 to $137.00 and set a "buy" rating on the stock in a research report on Tuesday, April 1st. Finally, Needham & Company LLC reduced their price objective on Vaxcyte from $140.00 to $90.00 and set a "buy" rating for the company in a research note on Tuesday, April 1st. Nine analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, Vaxcyte has a consensus rating of "Buy" and a consensus target price of $136.50.

Vaxcyte Stock Up 3.4 %

NASDAQ PCVX traded up $1.04 on Tuesday, reaching $31.60. The company had a trading volume of 5,690,652 shares, compared to its average volume of 1,119,961. The company's fifty day moving average is $74.59 and its 200 day moving average is $89.66. Vaxcyte has a 52-week low of $29.57 and a 52-week high of $121.06. The stock has a market capitalization of $4.07 billion, a P/E ratio of -6.87 and a beta of 1.26.

Remove Ads

Vaxcyte (NASDAQ:PCVX - Get Free Report) last announced its earnings results on Tuesday, February 25th. The company reported ($1.02) EPS for the quarter, beating the consensus estimate of ($1.16) by $0.14. On average, research analysts expect that Vaxcyte will post -4.21 EPS for the current year.

Insider Transactions at Vaxcyte

In other Vaxcyte news, COO Jim Wassil sold 8,000 shares of the stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $73.27, for a total transaction of $586,160.00. Following the completion of the transaction, the chief operating officer now owns 154,931 shares in the company, valued at $11,351,794.37. This trade represents a 4.91 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Teri Loxam sold 6,250 shares of Vaxcyte stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $85.11, for a total transaction of $531,937.50. Following the completion of the transaction, the director now owns 7,175 shares of the company's stock, valued at $610,664.25. The trade was a 46.55 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 38,250 shares of company stock worth $3,170,738. 3.10% of the stock is owned by company insiders.

Institutional Investors Weigh In On Vaxcyte

Institutional investors have recently made changes to their positions in the stock. Whipplewood Advisors LLC bought a new stake in shares of Vaxcyte during the 4th quarter valued at $28,000. Smartleaf Asset Management LLC grew its holdings in Vaxcyte by 188.4% during the 4th quarter. Smartleaf Asset Management LLC now owns 398 shares of the company's stock valued at $33,000 after buying an additional 260 shares in the last quarter. National Bank of Canada FI bought a new stake in shares of Vaxcyte during the fourth quarter valued at about $41,000. Blue Trust Inc. lifted its holdings in shares of Vaxcyte by 100.0% in the fourth quarter. Blue Trust Inc. now owns 742 shares of the company's stock worth $61,000 after buying an additional 371 shares in the last quarter. Finally, Assetmark Inc. lifted its holdings in shares of Vaxcyte by 77,500.0% in the fourth quarter. Assetmark Inc. now owns 776 shares of the company's stock worth $64,000 after buying an additional 775 shares in the last quarter. Hedge funds and other institutional investors own 96.78% of the company's stock.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.